Last reviewed · How we verify
Add Vildagliptin
At a glance
| Generic name | Add Vildagliptin |
|---|---|
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM (PHASE4)
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (PHASE2)
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors (PHASE4)
- Clinical Trial of Vildagliptin in Early Parkinson's Disease (NA)
- Empagliflozin Versus Vildagliptin in CAD Patients With T2DM (NA)
- Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
- Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus (PHASE2)
- Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Add Vildagliptin CI brief — competitive landscape report
- Add Vildagliptin updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI